Saka-Herrán Constanza, Jané-Salas Enric, Mano-Azul Antonio, Torrejón-Moya Aina, Estrugo-Devesa Albert, López-López José
Department of Odontostomatology, Faculty of Medicine and Health Sciences (Dentistry), University of Barcelona, 08970 Barcelona, Spain.
Oral Health and Masticatory System Group (Bellvitge Biomedical Research Institute) IDIBELL, Faculty of Medicine and Health Sciences (Dentistry), University of Barcelona, 08970 Barcelona, Spain.
Pharmaceuticals (Basel). 2022 May 6;15(5):579. doi: 10.3390/ph15050579.
Mechanisms related to the potential beneficial effects of statins on cancer are mainly related to the inhibition of the mevalonate pathway. The purpose of this study was to assess the association between prior use of statins and the risk of head and neck cancer. A hospital-based case-control study was conducted at the Dentistry Hospital of the University of Barcelona, including 101 incident cases of head and neck cancer and 101 controls matched to cases by age and sex. Multivariate logistic regression models were used to assess the association between prior statin exposure and head and neck cancer risk. Of the 202 patients included in total, 28.2% had previously received prescriptions for statins. Prior use of statins was found in 25.7% of cases and 30.7% of controls. Exposure to statins was not associated with head and neck cancer risk (OR = 0.72; 95% CI 0.28-1.84; = 0.49). There was also no time- or dose-dependent association. Similar trends were observed when analyzed by subsites of cancer and recurrence rate. Our findings do not support a beneficial effect of prior statin exposure on head and neck cancer risk. Future research relying on observational data should emulate randomized clinical trials before clinical implications for repurposing drugs can be drawn.
他汀类药物对癌症潜在有益作用的相关机制主要与甲羟戊酸途径的抑制有关。本研究的目的是评估既往使用他汀类药物与头颈癌风险之间的关联。在巴塞罗那大学牙科学院进行了一项基于医院的病例对照研究，纳入101例新发头颈癌病例和101例按年龄和性别匹配的对照。采用多因素logistic回归模型评估既往他汀类药物暴露与头颈癌风险之间的关联。在总共纳入的202例患者中，28.2%曾接受过他汀类药物处方。25.7%的病例和30.7%的对照曾使用过他汀类药物。他汀类药物暴露与头颈癌风险无关（比值比=0.72；95%置信区间0.28 - 1.84；P = 0.49）。也不存在时间或剂量依赖性关联。按癌症亚部位和复发率分析时观察到类似趋势。我们的研究结果不支持既往他汀类药物暴露对头颈癌风险有有益作用。在得出药物重新利用的临床意义之前，依赖观察性数据的未来研究应效仿随机临床试验。
